Navigation Links
David Bagley Joins Histogen as President
Date:1/14/2009

Regenerative Medicine Company Poised for Product and Business Development Successes in the New Year

San Diego, CA (PRWEB) January 14, 2009-- Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, announced today that David Bagley has joined the Company as President. Histogen welcomes Bagley following a year of rapid growth, with product launches, clinical evaluations and a new facility move on the horizon.

"With the launch of Histogen's first product, the creation of an aesthetics division, and talented new members joining the team in 2008, we've laid the groundwork for exciting progress in the coming year," said Dr. Gail Naughton, Histogen CEO and Chairman of the Board. "I am pleased to welcome David Bagley to Histogen, and believe his business experience and background in the field of tissue engineering will be a great asset to Histogen as we move forward."

David Bagley brings more than 20 years of cell biology and tissue engineering industry experience to Histogen. He has been a contributor to operational, scientific and engineering advancements in the development of several technologies including cell culture, tissue engineered and cell-based products for the treatment of multiple critical diseases, wound care and aesthetic product applications.

Most recently, Bagley served as Vice President and General Manager for Allergan Medical, Inc. with a focus on operations, technology, global distribution, quality and business disciplines. Prior to this, he held positions with Smith + Nephew/Advanced Tissue Sciences for over 12 years, where his latest position was Vice President of Technology and Logistics.

Previously, Bagley worked for Sigma Chemical Company where he was involved in the development and launch of several tissue culture product lines. Early in his career, he worked for HyClone Laboratories and Clonetics, both manufacturers and providers of cell culture products for various markets. Bagley has a B.S. degree in biology from Utah State University and a Master's degree in business from the American Graduate School of International Management in Arizona.

"Tissue engineering and cell-based products show a great deal of promise in the treatment of critical diseases and improving the lives of many people, however the development and launching of these complex products can be a challenge," said Bagley. "I am excited to join Histogen as President, and look forward to progressing these products and technologies to market."

About Histogen
Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products without the use of embryonic stem cells or animal products. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn fibroblasts are encouraged to naturally produce the vital proteins and growth factors from which the company has developed its rich product portfolio. Histogen has two product families - ExceltrixTM, Histogen's human Extracellular Matrix (ECM) and ReGenicaTM, Histogen's proprietary liquid formula. The Company recently launched its first product - BioNuesisTM Human Stem Cell Culturing Kits - and announced the creation of its cosmeceutical venture - Histogen Aesthetics. For more information, please visit www.histogeninc.com.

###

Read the full story at http://www.prweb.com/releases/Histogen/Bagley/prweb1861514.htm


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. BrainCells Inc. Appoints David E. Thompson to Its Board of Directors
2. Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast
3. PercSys Names David Auth and Howard Palefsky to Its Board of Directors
4. David H. Murdock Research Institute Taps Waters for Laboratory Technology
5. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
6. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
7. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
8. Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service
9. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
10. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
11. Omeros Appoints David A. Mann to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... Nova Oculus Partners has forged ... medical device for the treatment of Age-Related Macular Degeneration. , The company’s chief ... regulatory consultancy that helps companies like ours secure government approvals for their medical ...
(Date:1/21/2017)... LEAWOOD, Kan. , Jan. 20, 2017 ... pet therapeutics company focused on the licensing, development and ... Animal Pharm,s Best Company in ... was granted the award based on the ... ® (grapiprant tablets), ENTYCE ® (capromorelin oral ...
(Date:1/20/2017)... , January 20, 2017 ... market conditions have influenced the most recent performances of ... Inc. (NASDAQ: RGLS ), Abeona Therapeutics Inc. ... TBPH ), and Sage Therapeutics Inc. (NASDAQ: ... report by Grand View Research, global Biotech market size is expected ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... announced today the next evolution in spinal fusion, the MISquito Percutaneous Pedicle ... to the competition, SpineFrontier is focused on technique driven product solutions that ...
Breaking Biology Technology:
(Date:12/15/2016)... ... Markets has announced the addition of the "Global Military Biometrics Market ... the global military biometrics market to grow at a CAGR of 7.5% ... based on an in-depth market analysis with inputs from industry experts. The ... years. The report also includes a discussion of the key vendors operating ...
(Date:12/15/2016)... 14, 2016 "Increase in mobile transactions is ... mobile biometrics market is expected to grow from USD ... 2022, at a CAGR of 29.3% between 2016 and ... the growing demand for smart devices, government initiatives, and ... "Software component is expected to grow at a high ...
(Date:12/8/2016)... 2016  Singulex, Inc., the leader in Next Generation ... a license and supply agreement with Thermo Fisher Scientific, ... Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), a ... used to diagnose systemic bacterial infection and sepsis and ... aid in assessing the risk of critically ill patients ...
Breaking Biology News(10 mins):